Cargando…

FGFR1 expression defines clinically distinct subtypes in pancreatic cancer

BACKGROUND: The clinical significance of fibroblast growth factor receptor 1 (FGFR1) protein expression in pancreatic cancer is largely unknown. In this study, we aimed investigate the clinical significance of FGFR1 expression in pancreatic cancer. METHODS: First, we investigated the relationship be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haq, Farhan, Sung, You-Na, Park, Inkeun, Kayani, Mahmood Akhtar, Yousuf, Faizah, Hong, Seung-Mo, Ahn, Sung-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311038/ https://www.ncbi.nlm.nih.gov/pubmed/30593273 http://dx.doi.org/10.1186/s12967-018-1743-9

Ejemplares similares

FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
por: Raja, Aroosha, et al.
Publicado: (2019)

The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma
por: Ahn, Sung-Min, et al.
Publicado: (2018)

Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes
por: Wu, Fan, et al.
Publicado: (2022)

Replication Stress Defines Distinct Molecular Subtypes Across Cancers
por: Takahashi, Nobuyuki, et al.
Publicado: (2022)

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease
por: Ossenkoppele, Rik, et al.
Publicado: (2020)

FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
por: Ying, Xihui, et al.
Publicado: (2019)

Distinct Response of Circulating microRNAs to the Treatment of Pancreatic Cancer Xenografts with FGFR and ALK Kinase Inhibitors
por: Peran, Ivana, et al.
Publicado: (2022)

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma
por: Liu, Y J, et al.
Publicado: (2014)

EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma
por: Lucas, Calixto-Hope G., et al.
Publicado: (2021)

Genomic Relevance of FGFR2 on the Prognosis of HCV-Induced Hepatocellular Carcinoma Patients
por: Khan, Walizeb, et al.
Publicado: (2022)

FGFR2-ERC1: A Subtype of FGFR2 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Anlotinib
por: Hong, Chen, et al.
Publicado: (2022)

(18)F-labeled FGFR1 peptide: a new PET probe for subtype FGFR1 receptor imaging
por: Chen, Yang, et al.
Publicado: (2023)

Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma
por: Shin, Ji-Yon, et al.
Publicado: (2021)

Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
por: Lomberk, Gwen, et al.
Publicado: (2018)

MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks
por: Hacking, Sean, et al.
Publicado: (2023)

Mutational analysis of xenobiotic metabolizing genes (CYP1A1 and GSTP1) in sporadic head and neck cancer patients
por: Masood, Nosheen, et al.
Publicado: (2011)

Protection against laryngeal and pharyngeal carcinoma: Heterozygous vs. homozygous deletions of GSTM1 and GSTT1
por: Masood, Nosheen, et al.
Publicado: (2013)

Loss of Mitochondrial Tumor Suppressor Genes Expression Is Associated with Unfavorable Clinical Outcome in Head and Neck Squamous Cell Carcinoma: Data from Retrospective Study
por: Mahjabeen, Ishrat, et al.
Publicado: (2016)

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models
por: Zhang, H, et al.
Publicado: (2014)

Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
por: Georgescu, Maria-Magdalena, et al.
Publicado: (2021)

Blocking FGFR4 exerts distinct anti‐tumorigenic effects in esophageal squamous cell carcinoma
por: Xin, Zhongwei, et al.
Publicado: (2018)

Deciphering role of FGFR signalling pathway in pancreatic cancer
por: Kang, Xiaodiao, et al.
Publicado: (2019)

Cell polarity defines three distinct domains in pancreatic β-cells
por: Gan, Wan J., et al.
Publicado: (2017)

Distinct emphysema subtypes defined by quantitative CT analysis are associated with specific pulmonary matrix metalloproteinases
por: Ostridge, Kristoffer, et al.
Publicado: (2016)

An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
por: Tekpli, Xavier, et al.
Publicado: (2019)

Transcriptomic signature defines two subtypes of locally advanced PCa with distinct neoadjuvant therapy benefits
por: Zhu, Yinjie, et al.
Publicado: (2023)

Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer
por: Ansari, Adnan Ahmad, et al.
Publicado: (2018)

Molecular elements in FGF19 and FGF21 defining KLB/FGFR activity and specificity
por: Agrawal, Archita, et al.
Publicado: (2018)

Integrative landscape of dysregulated signaling pathways of clinically distinct pancreatic cancer subtypes
por: Sinkala, Musalula, et al.
Publicado: (2018)

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
por: Hyung, Sujin, et al.
Publicado: (2022)

High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma
por: Raffeld, Mark, et al.
Publicado: (2020)

Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
por: Mao, Ninghui, et al.
Publicado: (2021)

UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia
por: Duployez, Nicolas, et al.
Publicado: (2023)

FGFR2‐Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape
por: Klempner, Samuel J., et al.
Publicado: (2019)

Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion
por: Kim, Sun Young, et al.
Publicado: (2017)

Craniofacial divergence by distinct prenatal growth patterns in Fgfr2 mutant mice
por: Motch Perrine, Susan M, et al.
Publicado: (2014)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
por: Orben, Felix, et al.
Publicado: (2022)

A Radiomics-Based Model for Potentially More Accurate Identification of Subtypes of Breast Cancer Brain Metastases
por: Cho, Seonghyeon, et al.
Publicado: (2023)

IPCT: Integrated Pharmacogenomic Platform of Human Cancer Cell Lines and Tissues
por: Shoaib, Muhammad, et al.
Publicado: (2019)

Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations
por: Aoki, Kazunori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u1fbd6ch5n9gj3juk90qa0piml